Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768115 | 1.00 | HASPIN (0.39) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL20203577 | 0.81 | HASPIN (0.36) | HASPINMEN1KMT2AGAAHTT | |
| SCHEMBL30460896 | 0.79 | KMT2A (0.44) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL25275333 | 0.79 | KMT2A (0.44) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL27034848 | 0.78 | HASPIN (0.42) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL15507768 | 0.78 | HASPIN (0.42) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL20037627 | 0.77 | HASPIN (0.36) | HASPINPIM1TTKPIM2 | |
| SCHEMBL26181506 | 0.76 | HASPIN (0.35) | HASPIN | |
| SCHEMBL30460946 | 0.76 | HASPIN (0.39) | HASPINMEN1KMT2AALDH1A1GAA | |
| SCHEMBL25230364 | 0.76 | HASPIN (0.39) | HASPINMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | DPYD, TYMS, TYMP | HASPIN 3871/4885MEN1 3127/4885KMT2A 3390/4885 |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | HASPIN 2333/4885MEN1 1853/4885KMT2A 174/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | HASPIN 4471/4885MEN1 86/4885KMT2A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.